NCCN Qualifies Northside Hospital Cancer Institute for Affiliate Research Project
As the tenth approved member of the NCCN Affiliate Research Project (ARP), Northside Hospital Cancer Institute and its investigators and patients will gain access to new and innovative cancer drugs.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Affiliate Research Project (ARP), developed by the NCCN Oncology Research Program (ORP), has qualified Northside Hospital Cancer Institute for the project. Northside Hospital Cancer Institute is a community-based associate of the University of Alabama at Birmingham Comprehensive Cancer Center–one of the 23 NCCN Member Institutions.
"The newly established collaboration between NCCN and Northside Hospital Cancer Institute will benefit both patients and investigators involved in NCCN ORP-funded clinical trials," said Diane Paul, MS, RN, Vice President, NCCN ORP. "NCCN is excited to welcome Northside Hospital Cancer Institute as the newest affiliate in this landmark project."
Located in Atlanta, Georgia, with 33 satellite facilities across the state of Georgia, Northside Hospital Cancer Institute is operating as an NCCN ARP site under the leadership of Guilherme Cantuaria, MD, PhD, Medical Director and Principal Investigator, NCI Community Cancer Center Program at Northside Hospital Cancer Institute, and is the tenth community-based NCCN Member Institution affiliate to quality for the NCCN ARP, increasing the scope of potential patients for the more than 75 actively accruing ORP clinical trials. Northside Hospital Cancer Institute joins Medical Center of Central Georgia in representing the University of Alabama at Birmingham Comprehensive Cancer Center as a community-based affiliate in the project.
"We are delighted to be joining the NCCN ARP, as we continuously strive to offer our cancer patients access to the very latest in clinical trials, research, and treatments," said Dr. Cantuaria. "It remains paramount that Northside continues to provide the most comprehensive cancer care to our patients in order to offer them the very best clinical outcomes possible."
As part of the project, Northside Hospital Cancer Institute will have access to new and innovative cancer drugs for patients in collaboration with NCCN Member Institutions, and Principal Investigators of NCCN-funded studies will have access to Northside Hospital Cancer Institute as an NCCN-qualified community site.
The mission of the NCCN ARP is to improve patient outcomes and advance medical science through clinical research conducted collaboratively among the 23 NCCN Member Institutions and their community-based affiliate members.
In addition to Northside Hospital Cancer Institute and Medical Center of Central Georgia, affiliates within the project include Atlanticare Cancer Institute, South Jersey Healthcare, and Virtua, affiliates of Fox Chase Cancer Center; Bozeman Deaconess Hospital, MultiCare Health System, and Wenatchee Valley Medical Center, affiliates of Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; and Lehigh Valley Health Network and Norton Cancer Institute, affiliates of Moffitt Cancer Center.
The NCCN ORP is organized to obtain funding to support scientifically meritorious research projects at NCCN Member Institutions. Policies and standards for the program are set by the NCCN Investigator Steering Committee, a group comprised of senior research physicians appointed by each NCCN Member Institution. To date, the NCCN ORP has received more than $41 million in research grants from pharmaceutical and biotech companies to support investigator-initiated trials including, but not limited to, evaluation of innovative regimens, mechanism of action, and exploration of extended uses for specific agents.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital